Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | $0.32M |
| Net Income (Most Recent Fiscal Year) | $-10.26M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 43.56 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.23 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -3097.87% |
| Net Margin (Trailing 12 Months) | -3024.84% |
| Return on Equity (Trailing 12 Months) | -197.33% |
| Return on Assets (Trailing 12 Months) | -138.14% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.11 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.04 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.10 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.86 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 7.02M |
| Free Float | 4.70M |
| Market Capitalization | $16.28M |
| Average Volume (Last 20 Days) | 9607.65 |
| Beta (Past 60 Months) | 1.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 33.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 22.06% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |